Time filter

Source Type

Shanghai, China

Xiang Y.B.,Shanghai Cancer Institute
IARC scientific publications | Year: 2011

The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely done by passive methods. The registry contributed data on 52 cancer sites or types registered during 1992-1995 for this survival study. The methods of follow-up have been a mixture of both active and passive ones, with median follow-up ranging 3-81 months. The proportion with histologically verified diagnosis for various cancers ranged from 14-95%; death certificates only (DCOs) ranged from 0-2% and 98-100% of total registered cases were included for survival analysis. The top ranking cancers on 5-year age-standardized relative survival (%) were thyroid (90%), non-melanoma skin (86%), penis (84%), corpus uteri (82%) and testis (80%). The corresponding survival rates for common cancers were lung (16%), stomach (30%), liver (9%), breast (78%) and colon (48%). The 5-year relative survival by age group reveals an inverse relationship for most cancers. An increasing trend in the 5-year absolute andrelative survival was noted for all cancers registered in 1992-1995 compared to 1988-1991.

This invention belongs to the nanotechnology field, and discloses a nano drug delivery system with polyethyleneglycol-poly(lactic-co-glycolic acid)-poly-L-lysine (PEG-PLGA-PLL) polymer as the skeleton. The carrier can have the function of passive targeting through control of the carrier particle size. The polymer skeleton is modified through introducing side chains and specific targeting groups, so as to adjust and improve the carrier performance, and enable the carrier to have the function of active targeting. Such carrier material also has the functions of transporting active substances, tumor treatment and diagnosis, ultrasonic contrast, reversing or reducing drug resistance and so on. It is mainly applied to (1) Targeting preparation of anticancer drugs; (2) preparation to reverse or reduce the drug resistance of the tumor; (3) reagent for tumor diagnosis and contrast; (4) reagent to transfect DNA plasmids; (5) pharmaceutical preparation for cancer gene therapy; (6) reagent used to transfect antisense nucleic acid and siRNA (RNA interference); (7) pharmaceutical preparation used to prepare antisense nucleic acid and siRNA (RNA interference).

A vascular embolization gelling agent for sustained release of drugs for treating tumors having a drug and a drug carrier. The drugs are antitumor drugs. The drug carrier includes poloxamer polymer and polyvinylpyrrolidone or gel made of the combination, and may be purified before use. The drug carrier accounts for 5-65% of the gel. The particle size of the gel is in the range of 10 nm-150 m. The embolization agent is a liquid gel at normal temperature, to facilitate direct transcatheter injection, and is rapidly solidified to the gel state in body with the increase of the temperature; it is used to encapsulate different drugs on demand, and can achieve dual efficacy of embolization and drug treatment through local sustained release of the drug. The present invention can be used as the embolization agent for endovascular interventional therapy for transcatheter arterial chemoembolization of various benign and malignant tumors.

Shanghai Cancer Institute | Date: 2011-01-26

Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Shanghai Cancer Institute | Date: 2012-08-09

Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Discover hidden collaborations